// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Age-associated b cells in early drug-naÏve rheumatoid arthritis patients

A.E. Anderson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Rituximab

Alarmins s100a8 and s100a9 modulate the inflammatory microenvironment in early tendinopathy

L.A.N. Crowe - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART study: baseline characteristics of the randomised patient population

I. Mackenzie - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

Allopurinol

An anatomically distinct pathogenic fibroblast subset drives inflammation in arthritis

A.P. Croft - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

An audit of the use of percutaneous vertebroplasty for osteoporotic vertebral fractures in a uk rheumatology clinic

J. Pinnell - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Acetaminophen

An audit on paediatric uveitis in the greater glasgow and clyde (GGC service: guideline adherence and impact on patient outcomes

E. Parmar - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Uveitis

N/A

An audit on the screening guidelines for uveitis in children with juvenile idiopathic arthritis within the royal hospital for children, glasgow

J. Waddell - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

An increased prevalence of periodontal disease, porphyromonas gingivalis and aggregatibacter actinomycetemcomitans in anti-ccp positive individuals at-risk of inflammatory arthritis

K. Mankia - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Arginine hydrochloride

An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies

D.D. Gladman - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Tasocitinib

Analytical validation of an interferon-inducible gene expression kit as a potential diagnostic test for anifrolumab

P.K. Brohawn - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

MDX1333

Anti-tnf treatments for women with chronic inflammatory diseases: comparing attitudes and perceptions of physicians in europe and the us

A. Tincani - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antibodies to post-translationally modified collagen ii in spondyloarthritis

C. Vinci - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

ribose

Application of machine learning methods for prediction modelling of psoriatic arthritis in patients with psoriasis

F. Jalali-najafabadi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Are bisphosphonates solely responsible for atypical femoral fractures? a case series

M.S. Jamal - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Glucocorticoid

Are disease activity, disability or psychological factors most associated with patients with rheumatoid arthritis being satisfied with their condition after 12 months following treatment onset?

J. Gwinnutt - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Are micrornas a molecular clock? the newcastle thousand families cohort study

T.L. Jones - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Asas consensus on spanish nomenclature for spondyloarthritis

V. Navarro-Compán - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Assessing the burden of treated and untreated chronic low back pain in europe

M.J. Doane - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic low back pain

N/A

Assessing the burden of treated and untreated osteoarthritis pain in europe

M.J. Doane - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Assessment of acr and slicc classification criteria in the asia pacific lupus collaboration cohort

R. Kandane-Rathnayake - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

N/A

Copyright © 2026. QuantiNova All rights reserved